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Background: Patients with irritable bowel syndrome (IBS) experience abdominal pain, altered bowel habits, and defecation-related
anxiety, which can result in reduced productivity and impaired health-related quality of life (HRQL). Cognitive behavioral therapy
(CBT) has been shown to reduce symptoms of IBS and to improve HRQL, but access to qualified therapists is limited.
Smartphone-based digital therapeutic interventions have potential to increase access to guided CBT at scale, but require careful
study to assess their benefits and risks.
Objective: The aim of this study was to test the efficacy of a novel app, Zemedy, as a mobile digital therapeutic that delivers
a comprehensive CBT program to individuals with IBS.
Methods: This was a crossover randomized controlled trial. Participants were recruited online and randomly allocated to either
immediate treatment (n=62) or waitlist control (n=59) groups. The Zemedy app consists of 8 modules focusing on psychoeducation,
relaxation training, exercise, the cognitive model of stress management, applying CBT to IBS symptoms, reducing avoidance
through exposure therapy, behavioral experiments, and information about diet. Users interact with a chatbot that presents the
information and encourages specific plans, homework, and exercises. The treatment was fully automated, with no therapist
involvement or communication. At baseline and after 8 weeks, participants were asked to complete the battery of primary (Irritable
Bowel Syndrome Quality of Life [IBS-QOL], Gastrointestinal Symptom Rating Scale [GSRS]) and secondary (Fear of Food
Questionnaire [FFQ], Visceral Sensitivity Index [VSI], Gastrointestinal Cognition Questionnaire [GI-COG], Depression Anxiety
Stress Scale [DASS], and Patient Health Questionnaire-9 [PHQ-9]) outcome measures. Waitlist controls were then offered the
opportunity to crossover to treatment. All participants were assessed once more at 3 months posttreatment.
Results: Both intention-to-treat and completer analyses at posttreatment revealed significant improvement for the immediate
treatment group compared to the waitlist control group on both primary and secondary outcome measures. Gains were generally
maintained at 3 months posttreatment. Scores on the GSRS, IBS-QoL, GI-COG, VSI, and FFQ all improved significantly more
in the treatment group (F1,79=20.49, P<.001, Cohen d=1.01; F1,79=20.12, P<.001, d=1.25; F1,79=34.71, P<.001, d=1.47; F1,79=18.7,
P<.001, d=1.07; and F1,79=12.13, P=.001, d=0.62, respectively). Depression improved significantly as measured by the PHQ-9
(F1,79=10.5, P=.002, d=1.07), and the DASS Depression (F1,79=6.03, P=.02, d=.83) and Stress (F1,79=4.47, P=.04, d=0.65)
subscales in the completer analysis but not in the intention-to-treat analysis. The impact of treatment on HRQL was mediated by
reductions in catastrophizing and visceral sensitivity.
Conclusions: Despite its relatively benign physical profile, IBS can be an extraordinarily debilitating condition. Zemedy is an
effective modality to deliver CBT for individuals with IBS, and could increase accessibility of this evidence-based treatment.
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Irritable bowel syndrome (IBS) is a chronic gastrointestinal
(GI) disorder of multifactorial etiology that is characterized by
abnormal centralized pain processing. IBS is defined by
recurrent abdominal pain occurring at least one day per week
in the last 3 months, associated with two or more of the
following: related to defecation, associated with changes in the
frequency or form of bowel movements (ie, characterized by
constipation, diarrhea, or an alternating mix of the two). IBS is
highly prevalent, affecting up to 10% of the US population.
Many studies have demonstrated that IBS has high rates of
psychiatric comorbidity (up to 90% in treatment-seeking
patients) [1,2], and causes social and occupational impairment
[3]. Beyond the core symptoms of abdominal pain and altered
bowel habits, individuals with IBS suffer from a host of related
difficulties that substantially impair health-related quality of
life (HRQL) and functioning. Visceral hypersensitivity, common
among IBS patients, is a phenomenon in which people feel
normal gut sensations that most people would be unaware of,
and experience many of these sensations as more painful
compared with healthy controls [4]. Anxiety and visceral
hypersensitivity are highly correlated [5]. Anxiety and
hypervigilance related to the sensations exacerbate the
hypersensitivity [6].
Illness-related anxiety is high among patients with IBS, and is
a better predictor of impairment in quality of life than actual
symptom severity [7]. A major component of this anxiety is
“catastrophizing,” in which individuals envision the worst
possible outcome of their GI symptoms and in turn develop
maladaptive coping strategies [3]. Catastrophizing is highly
correlated with impairment in HQRL for patients with IBS [8].
Because of their catastrophizing, many individuals with IBS
engage in significant avoidance behavior that can easily meet
the diagnostic criteria for agoraphobia [9].
Cognitive Behavioral Therapy for IBS
Over the past two decades, cognitive behavioral therapy (CBT)
has repeatedly proven to be an efficacious treatment for
individuals suffering from IBS [10,11]. Specifically, there is
empirical support that CBT reduces GI symptom severity and
impairment in quality of life [12,13]. These CBT treatments
typically include components of psychoeducation about the
brain-gut axis, mindfulness and relaxation training [14], reducing
automatic negative thoughts related to GI catastrophizing [15],
exposure therapy to feared and avoided sensations and situations
[16], and reducing visceral hypersensitivity [12]. One
meta-analysis including 20 psychological treatments for IBS
found that GI cognition change and GI-specific anxiety were
important mediators in improving GI-related quality of life and
GI symptom severity [17].
Although CBT is a promising treatment, access to IBS-specific
CBT remains low for patients. There is a lack of clinicians
competent in delivering GI-specific CBT [3]. Additionally, the
cost of treatment looms high; individuals often lack insurance
coverage for psychotherapy and must pay out of pocket, which
can be burdensome given the hundreds of dollars their IBS
likely already costs them [18]. It is therefore necessary to
develop a cheaper, more easily accessible alternative mode of
treatment.
Many groups have tested variants of CBT for IBS with limited
or distant therapist involvement (eg, via email) [15,19] and
typically obtain robust effect sizes. These studies generally
showed that web-based and telephone-based CBT improved
IBS more than treatment as usual (eg, [20]). Several treatment
manuals and self-help books are available that detail the CBT
treatment approach, and one [21] was found to be efficacious
as a stand-alone treatment in a randomized controlled trial (RCT)
[22].
In today’s digitized world, the mobile health (mHealth) industry
is growing. The industry is currently valued at close to US $50
billion and is expected to multiply by nearly five times over the
next decade [23]. Thousands of mobile apps exist to improve
health across the spectrum. Mobile apps have multiple
advantages, including low cost, privacy, accessibility, and
convenience for the user.
CBT is among the forms of treatment increasingly being
delivered via apps. In their review of eight CBT apps, Rathbone
et al [24] found that CBT self-help apps can be efficacious, most
notably in alleviating depressive symptoms. They also cited the
willingness of participants to engage in therapy as a key
component of the apps’ success [24]. A component of many
mHealth apps, and specifically those that use CBT, is automated
guidance and feedback. Automated guidance has been found to
be effective in reducing substance abuse among urban women
and emerging adults [25,26]. Kelders et al [27] compared an
automated treatment for depression with standard, in-person
clinical treatment and found that depressive symptoms were
moderately reduced for those in the automated group, although
not as strongly as found for the in-person treatment group.
However, Mason and Andrews’ [28] internet CBT study found
that “specialist assessments and initial face-to-face contact do
not influence treatment outcome, and that patients do just as
well with an automated assessment.” Hauser-Ulrich et al [29]
developed a smartphone app to treat chronic pain through CBT.
This app employs a chatbot that guides users through modules
[29]. In their RCT, the authors found improvements in
pain-related impairment, pain intensity, and general well-being
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for those who used the app for 8 weeks [29]. Thus, there is
strong evidence to suggest that automated treatment in a CBT
app may be highly effective in delivering integrative behavioral
health care for patients with disorders at the boundary between
physical symptoms and psychological distress.
Aim
As self-help modalities are increasingly available online and
through smartphone apps, it is important to test the efficacy of
those apps through rigorous, controlled research. The purpose
of this study was to test the efficacy of a novel digital app
(Zemedy) that applies CBT to IBS.
Methods
Trial Registration
This study was approved by the Institutional Review Board of
the University of Pennsylvania. All participants provided
electronic consent prior to participation in the study. The
deidentified dataset analyzed in the study is available from the
corresponding author upon request. This trial was registered at
ClinicalTrials.gov as NCT04170686.
App Description
Zemedy 1.0 is a mobile phone app designed by Bold Health, a
UK-based digital health company, in collaboration with the
principal investigator (MH) based on her empirically supported
self-help book [21]. The app treats IBS through CBT specifically
developed for the condition. Users of either iOS or Android
smartphones are guided through the app by a chatbot with whom
they “text.” The app consists of 10 modules. The first two
modules are devoted to psychoeducation about the etiology of
IBS and CBT’s effectiveness in treating it. The remaining eight
modules teach users about various CBT strategies to mitigate
the impact of IBS on daily life, including relaxation training,
exercise, cognitive restructuring and decatastrophizing, exposure
exercises to reduce avoidance, and behavioral experiments. It
also encourages a healthy (but not highly restrictive) diet. See
Figure 1 for screenshots of the Zemedy app. Users are prompted
to apply these strategies to their daily lives. Similar to the
chronic pain treatment developed by Hauser-Ulrich et al [29],
Zemedy is designed to be completed in 8 weeks. Participants
were encouraged to read through the first 5 modules (education,
relaxation training, and exercise) in the first week, and to
practice relaxation exercises daily. The remaining modules were
designed to be worked through approximately one per week,
with practice and homework exercises performed daily to learn
and apply the skills.
Figure 1. Screenshots of Zemedy.
The app also includes a “flare module,” which users can access
at any point to address immediate GI pain and anxiety. Shah et
al [14] found that mind-body interventions such as relaxation
training and hypnosis have moderate effect sizes in reducing
IBS symptoms. The flare module contains a variety of exercises
such as deep breathing, progressive muscle relaxation, relaxation
imagery, and hypnotherapy scripts that help mitigate distress
and discomfort in the moment.
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Participants were provided with a link to download the app.
They were provided the app at no cost. The entire intervention
was delivered within the app with no human involvement (eg,
therapist guidance or feedback). If participants experienced
technical difficulties, they could reach out to technical support
at Bold Health. They received a single email at 4 weeks from
a research coordinator in the trial providing general
encouragement to continue working through the app (if they
were in the immediate treatment group) or to “hang in there”
(if they were in the waitlist control group).
Design
This was a randomized waitlist control crossover trial with
assessments performed at baseline, postintervention (8 weeks),
following crossover to intervention for the waitlist control group,
and at follow-up (3 months postintervention). After completing
the consent and all baseline measures, participants were
randomly allocated by a research coordinator to either the
immediate treatment or waitlist control group using the coin
toss function of random.org. After 8 weeks, all participants were
asked to complete the same battery of measures. At that point,
participants in the waitlist group were crossed over and were
given access to the app. After 8 weeks of access, they were
asked to complete the battery of questionnaires again. All
participants were then assessed one final time 3 months after
completing the treatment phase. Unfortunately, the onset of the
COVID-19 pandemic coincided with the follow-up portion of
the trial, and it is unclear the extent to which the pandemic
affected both attrition and long-term results.
Sample Size
The power analysis showed that 30 participants per randomized
group would have 85% statistical power at a two-sided
significance level of .05 to detect an effect size of 0.76. The
effect size was chosen as previous studies of internet-delivered
CBT for IBS reported similar effect sizes for HRQL and GI
symptoms outcomes [15,22]. Assuming 50% attrition, as is
common in internet-based intervention studies, we aimed to
recruit 120 participants to have ample power to detect main
effects, and to explore potential mediators and moderators.
Inclusion and Exclusion Criteria
Inclusion criteria consisted of being 18 years of age or older,
and reporting having been previously diagnosed by a physician
with IBS or meeting the Rome IV criteria by self-report. We
did not specify a time frame for the physician diagnosis;
therefore, it is possible that some participants were originally
diagnosed under Rome III criteria. Owning a smartphone and
computer/internet literacy were de facto eligibility criteria.
Exclusion criteria consisted of reporting having received a
diagnosis of another comorbid GI disorder such as celiac disease
or an inflammatory bowel disease. Exclusion criteria also
included severe depression and/or suicidal ideation, defined as
a score of 20 or above on the Patient Health Questionnaire-9
(PHQ-9), and/or positive endorsement of active suicidal ideation
or intent on a separate suicide question. Twenty-five individuals
met this criterion. They were excluded from the trial, but were
given immediate access to the app. The principal investigator,
who is a licensed clinical psychologist, followed up with each
of these individuals to complete a risk assessment and offer
other resources such as referrals to local in-person providers.
Participants
A total of 146 potential participants were screened, 121 of whom
met the inclusion criteria. Participants were recruited for the
trial through IBS-specific social media sites with a combination
of graphic advertisements, and posts and comments on threads
informing site users about the study. Most participants came to
the study through Facebook (n=30), Twitter (n=32), and the
IBS subReddit (n=51). There were no face-to-face components
to the trial in terms of recruitment, assessment, or intervention.
Posts and advertisements included a link to a secure University
of Pennsylvania Qualtrics study page. On following the link,
potential participants would first see the detailed explanation
of the research (consent form; see Multimedia Appendix 1) and
would consent to completing the baseline questionnaires.
Questionnaires were completed via Qualtrics and could be
downloaded securely by the research team. Participants were
identified by email during data collection. All data were stored
in a deidentified format. All recruitment and follow-up occurred
between October 1, 2019 and November 1, 2020. The trial ended
upon successful completion.
All but five participants reported that they had been diagnosed
with IBS by a physician at some point (which could have been
under Rome III or Rome IV criteria). The five participants who
did not report a physician diagnosis all met stringent Rome IV
criteria by self-report. Of the 30 (24.8%) participants who
reported a physician diagnosis but did not meet stringent Rome
IV criteria, 7 reported pain 3 days a month and would have met
Rome III criteria. Another 5 participants reported even less
frequent pain. Four women reported pain solely during their
menstrual period. Four people failed to meet the duration criteria
(less than 6 months total since onset). The final 10 participants
met only one, rather than two, of the three criteria beyond
frequent abdominal pain.
With respect to IBS subtype, 48 (39.7%) participants reported
diarrhea-predominant IBS, 28 (23.1%) reported mixed subtype,
11 (9.1%) reported constipation-predominant IBS, and 4 (3.3%)
reported undifferentiated IBS. The remaining 30 (who did not
meet all Rome IV criteria) were not divided into subtypes.
Randomization and Blinding
Participants who met the inclusion criteria were allocated to
condition using the coin toss feature of random.org. A total of
62 participants were assigned to the immediate treatment
condition and 59 were assigned to the waitlist control. The
allocation sequence was concealed to participants until they
were enrolled, had completed baseline data collection, and had
been assigned to a group. The majority of baseline symptom
severity measures were not significantly different between the
immediate treatment and waitlist control groups. However,
participants in the waitlist control group reported significantly
more depression and more impaired HRQL than those in the
immediate treatment group. Although the design should have
yielded a low risk of bias from randomization, the slight
differences in symptom severity at baseline suggest some
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concerns about randomization, according to the Cochrane risk
of bias tool [30].
Because of the nature of the trial (immediate treatment versus
waitlist control group), neither participants nor research
coordinators were blinded to condition. However, there were
no deviations from the intended intervention. Moreover, all
outcome data were self-reported. Thus, blinding of evaluators
was neither possible nor necessary.
Procedure
Participants in the immediate treatment group were given the
link to access the Zemedy app, and were encouraged to
download it and begin working through the modules
immediately. The waitlist control group was told they would
be given access to the app in 8 weeks. Four weeks after baseline,
participants in the treatment group were emailed to encourage
them to continue using the app, and the waitlist control group
was emailed to offer encouragement, remind them they were
still enrolled in the study, and let them know that they would
be receiving the follow-up questionnaires in 4 weeks.
Eight weeks after completing the baseline questionnaire, all
participants were emailed a link to a second Qualtrics page that
contained all of the same measures as completed at baseline.
Those in the waitlist control condition were then given access
to the app.
After having had access to the app for 8 weeks, participants in
the waitlist control group were emailed a link to the third battery
of questionnaires that was identical to the battery received by
the treatment group after 8 weeks of app usage, which included
the same measures as contained in the baseline battery.
Finally, all participants were emailed a final link to the last
battery of questionnaires (again identical to the battery at
baseline and posttreatment) 3 months after they completed the
active treatment phase. Upon completion of each round of
questionnaires, participants received US $20 in Amazon credit.
If at any point a participant had indicated a significant increase
in depressive symptoms or the onset of suicidal ideation, the
team would have alerted the principal investigator (a licensed
clinical psychologist) who would have reached out to that
individual to perform a risk assessment and offer referrals to
local resources. No such adverse events occurred.
Primary Outcome Measures
IBS-Quality of Life
The IBS-Quality of Life (IBS-QOL) questionnaire is a 34-item
self-report measure specific to IBS designed to assess the impact
of IBS on quality of life [31,32]. The IBS-QOL has high internal
consistency (Cronbach α=.95), high reproducibility (intraclass
correlation coefficient=0.86), and good construct validity [32].
Qualitative score ranges are 0-31 (minimal or mild), 32-66
(moderate), and 67-100 (severe impairment).
Gastrointestinal Symptom Rating Scale-IBS
The Gastrointestinal Symptom Rating Scale-IBS (GSRS-IBS)
contains 13 self-report items rated on a 6-point Likert scale
ranging from 1 (no discomfort at all) to 7 (very severe
discomfort) [33]. Total scores range from 0 to 78. The
GSRS-IBS has 5 subscales, including abdominal pain, bloating,
constipation, diarrhea, and satiety. Each dimension has
demonstrated high internal consistency, with Cronbach α
ranging from .74 (pain) to .85 (satiety). Furthermore, the GSRS-
IBS has demonstrated both high test-retest reliability, with
intraclass correlations among the factors ranging from 0.55
(pain) to 0.70 (bloating), as well as high construct validity [33].
Overall internal consistency was good in our sample with
Cronbach α=.81. The GSRS has been used as a primary outcome
measure in several recent RCTs of IBS treatments [9], and the
Rome Foundation reports that it is shorter and more user-friendly
than the IBS Severity Scoring System [34]. Qualitative score
ranges are 0-20 (minimal or mild), 21-39 (moderate), and 40-78
(severe).
Secondary Outcome Measures
Rome IV Criteria Questionnaire
We used a questionnaire to determine whether participants met
the current Rome IV diagnostic criteria for IBS. Our
questionnaire was based on the Rome IV IBS-Specific
Questionnaire, which is a validated self-report scale that covers
the diagnostic criteria for IBS. It has been found to have
acceptable sensitivity and high specificity as well as good
test-retest reliability [35]. We used a modified, shortened version
with 10 items that covered all diagnostic criteria.
Fear of Food Questionnaire
The Fear of Food Questionnaire (FFQ) is an 18-item self-report
questionnaire that measures fear, avoidance of food, as well as
life interference and loss of pleasure from eating [36]. Items are
rated on a Likert scale ranging from 0 (not at all) to 5
(absolutely). It has excellent internal consistency reliability with
Cronbach α=.96 and strong 2-week test-retest reliability at
r=0.93, P<.001 [36]. The FFQ also shows good criterion and
known-groups validity [36]. Qualitative score ranges are 0-15
(minimal), 16-30 (mild), 31-45 (moderate), and 46-90 (severe).
Visceral Sensitivity Index
The Visceral Sensitivity Index (VSI) is a unidimensional 15-item
scale that measures GI symptom–specific anxiety [6,37]. Items
are rated on a Likert scale ranging from 0 (strongly disagree)
to 5 (strongly agree). It has high internal consistency (Cronbach
α=.93) and a mean interitem correlation of 0.47 [37,38]. It has
good criterion, construct, and predictive validity [6]. Qualitative
score ranges are 0-10 (minimal or mild), 11-30 (moderate), and
31-75 (severe).
Gastrointestinal Cognitions Questionnaire
The Gastrointestinal Cognitions Questionnaire (GI-COG)
consists of 16 self-report items that are rated on a 5-point Likert
scale, ranging from 0 (hardly) to 4 (very much). Individual items
are summed and total scores range from 0 to 64. The
questionnaire consists of three subscales: the pain/life
interference subscale (eg, “When I feel my GI symptoms acting
up, I’m afraid the pain will be excruciating and intolerable”),
the social anxiety subscale (eg, “If I have to get up and leave
an event, meeting, or social gathering to go to the bathroom
people will think there’s something wrong with me”), and the
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disgust sensitivity subscale (eg, “The thought of fecal
incontinence is terrifying. If it happened, it would be awful”).
The GI-COG has been shown to have excellent internal
consistency (Cronbach α=.92) and test-retest reliability (r=0.87,
P=.001) [39]. Qualitative score ranges are 0-19 (minimal or
mild), 20-39 (moderate), and 40-64 (severe).
Depression Anxiety Stress Scale
The Depression Anxiety Stress Scale (DASS) is a 42-item
self-administered questionnaire that measures the magnitude
of depression, anxiety, and stress independently. Internal
consistency for each of the subscales of the questionnaire are
high, with Cronbach α of .96 to .97 for DASS-Depression, .84
to .92 for DASS-Anxiety, and .90 to .95 for DASS-Stress
[40,41]. The DASS has been found to be a highly reliable and
valid measure of the constructs it is intended to assess [42].
PHQ-9 Assessment
The PHQ-9 is a depression scale that consists of 9 self-report
items. The 9 items aim to quantify the 9 criteria upon which the
diagnosis of depressive disorders is based in the Diagnostic and
Statistical Manual of Mental Disorders-IV. The PHQ-9 can
establish a depressive disorder diagnosis and depressive
symptom severity [43]. Each of the 9 items can be scored from
0 (not at all) to 3 (nearly every day); therefore, scores can range
from 0 to 27. The PHQ-9 has been found to demonstrate high
internal reliability, with Cronbach α of .89 when tested in a
primary care setting and .86 when tested in an
obstetrics-gynecology setting [43].
Dose
Dosage was measured according to the number of modules
completed. The mobile app sent usage data to the backend
system each time a participant visited the app. Data include the
time and date of each session on the app.
Statistical Analysis
Univariate general linear models in SPSS V25 were used to
examine between-group effects at posttreatment (8 weeks),
controlling for baseline levels of the dependent variable.
Paired-sample t tests were used to examine within-group
changes over the treatment phase for each group and
maintenance of gains from posttreatment to 3-month follow-up.
The robustness of these analyses was examined in an
intention-to-treat sensitivity analysis using multiple imputation.
As shown below, missing data at follow-up were not entirely
missing at random. Therefore, baseline outcome measures were
included in the imputation model as predictors together with
the follow-up set of measures with missing data and imputation
using the fully conditional specification [44] performed to create
15 imputed datasets. Regression models were then fitted as in
the primary analysis, and pooled estimates of the treatment
effect were calculated. Three sets of imputed datasets were
created, one for each follow-up data point, with baseline
measures included in each.
Change in visceral anxiety, catastrophizing, and fear of food
(calculated as the change from baseline to 8 weeks) were
explored as possible mediators of GI symptoms and quality of
life at 8 weeks using regression analysis with estimates of
indirect effects calculated using a percentile bootstrap estimation
approach with 5000 samples implemented with the PROCESS
macro Version 3.5 [45]. Both direct and indirect effects are
reported. The direct effect quantifies the estimated difference
in the dependent variable (GI symptoms or quality of life)
between two cases that are equal on the mediator but differ by
one unit on treatment assignment (ie, intervention vs waitlist
group). The indirect effect quantifies how much two cases, one
assigned to immediate treatment and the other to waitlist, are
estimated to differ on the dependent variables (GI symptoms
or quality of life) as a result of the treatment’s influence on the
mediator, which in turn influences the dependent variable. Two
sets of models were fitted: the first tested the mediator variables
separately with simple mediator models, and the second fitted
a parallel mediator model where the three mediators were tested
simultaneously. The baseline level of the dependent variable
was included as a covariate in all mediation models.
Results
Participant Characteristics
The mean participant age was 32 years (SD 10.2, range 18-63).
Of the total 121 participants, 76.0% (n=92) were white, 5.8%
(n=7) were Hispanic, 5.0% (n=6) were black, 4.1% (n=5) were
Asian, and the remaining 9.1% (n=11) identified as mixed race
or other. With respect to gender, 75.2% (91/121) identified as
female and 24.8% (30/121) identified as male. With respect to
marital status, 43.0% (52/121) reported being single, 32.2%
(39/121) reported being married, 19.0% (23/121) reported
having a partner or cohabiting, and 5.8% (7/121) reported being
divorced at baseline. With respect to employment, 22.3%
(27/121) of the participants were students, 15.7% (19/121)
reported being employed part time, 47.9% (58/121) reported
being employed full time, and 14.0% (17/121) reported that
they were not working when completing the baseline surveys.
See Figure 2 for the CONSORT diagram of participant flow
through the study.
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Figure 2. CONSORT diagram of participant flow through the study.
There were no significant differences between the immediate
treatment and waitlist control groups on any of the demographic
variables, or in baseline GI symptoms, visceral sensitivity,
catastrophizing, or fear of food. However, as noted above, the
waitlist control group was found to be slightly more distressed
than the treatment group at baseline. The waitlist control group
reported significantly more depression (PHQ-9, t119=2.99,
P=.003; DASS-Depression t119=2.11, P=.04) and more impaired
quality of life (t119=2.04, all P=.04) than the immediate treatment
group, although effect sizes were modest (d=0.38 for the DASS,
d=0.54 for PHQ-9, and d=0.37 for IBS-QOL). Thus, baseline
symptoms were controlled in all analyses.
There were no univariate outliers found at baseline.
Outcomes
Completer analyses assessing the impact of treatment on
outcome at 8 weeks revealed significant improvement for the
immediate treatment group, relative to the waitlist control group,
for both primary outcomes of GI symptom severity and HRQL
(F1,79=20.12, P<.001, Cohen d=1.02 and F1,79=20.49, P<.001,
d=1.25, respectively). With respect to the secondary outcome
measures, GI-specific catastrophizing, visceral anxiety, and fear
of food all improved significantly more in the treatment group
(F1,79=34.71, P<.001, d=1.47; F1,79=18.7, P<.001, d=1.07; and
F1,79=12.13, P=.001, d=0.62, respectively). Finally, depression
improved significantly more in the immediate treatment group
as measured by both the PHQ-9 (F1,79=10.5, P=.002, d=1.07),
and the DASS Depression (F1,79=6.03, P=.02, d=0.83) and
Stress (F1,79=4.47, P=.04, d=0.65) subscales. Only the DASS
Anxiety subscale failed to show a significant advantage for the
treatment group (F1,79=1.84, P=.18, d=0.41). See Table 1 for
all means and SDs across all assessment timepoints. These
results were replicated in the intention-to-treat analyses using
multiple imputation, with the exception of the PHQ-9 and DASS
scores, which were nonsignificant (Table 2).
For the immediate treatment group, all of the outcome variables
changed significantly from pretreatment to posttreatment with
the exception of the DASS Depression subscale, which showed
only marginally significant improvement (Table 3). Sensitivity
analysis using multiple imputation found the same pattern of
significance.
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43.98 (21.1)38.08 (18.42)76.6 (20.07)58.19 (18.53)34.25 (19.78)60.48 (18.29)53.63 (18.67)IBS-QOLa
30.95 (11.88)27.83 (9.37)34.26 (14.98)38.18 (10.79)27.56 (10.12)37.75 (12.02)36.76 (12.77)GSRSb
31.71 (14.11)23.75 (12.06)33.3 (12.34)40.84 (11.23)22.44 (13.72)40.07 (12.04)36.92 (13.35)GI-COGc
45.00 (12.63)41.08 (14.13)46.43 (12.78)53.57 (12.37)38.14 (16.21)53.54 (11.44)51.74 (12.29)VSId
42.38 (19.87)42.83 (20.99)46.10 (19.87)53.75 (18.08)41.22 (22.23)55.46 (18.21)52.87 (19.14)FFQe
10.33 (5.97)6.92 (5.71)10.30 (5.80)10.32 (4.29)5.78 (4.20)11.03 (4.66)8.32 (5.29)PHQf
DASSg
16.38 (12.89)9.08 (8.26)14.43 (10.89)15.45 (10.39)7.83 (7.88)15.59 (10.69)11.65 (9.88)Depression
16.86 (9.69)15.08 (8.40)18.78 (10.03)18.82 (9.99)12.72 (8.65)18.71 (8.97)17.84 (9.56)Stress
10.00 (6.99)9.08 (7.76)11.83 (9.72)12.05 (9.72)8.67 (6.38)12.19 (9.14)12.03 (7.35)Anxiety
aIBS-QOL: IBS Quality of Life.
bGSRS: Gastrointestinal Symptom Rating Scale.
cGI-COG: Gastrointestinal Cognitions Questionnaire.
dVSI: Visceral Sensitivity Index.
eFFQ: Fear of Food Questionnaire.
fPHQ: Patient Health Questionnaire.
gDASS: Depression Anxiety Stress Scale.
Table 2. Significance of treatment allocation at 8 weeks using multiple imputation.











aIBS-QOL: IBS Quality of Life.
bGSRS: Gastrointestinal Symptom Rating Scale.
cGI-COG: Gastrointestinal Cognitions Questionnaire.
dVSI: Visceral Sensitivity Index.
eFFQ: Fear of Food Questionnaire.
fPHQ: Patient Health Questionnaire.
gDASS: Depression Anxiety Stress Scale.
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Table 3. Improvement from baseline to posttreatment for the immediate treatment group.











aIBS-QOL: IBS Quality of Life.
bGSRS: Gastrointestinal Symptom Rating Scale.
cGI-COG: Gastrointestinal Cognitions Questionnaire.
dVSI: Visceral Sensitivity Index.
eFFQ: Fear of Food Questionnaire.
fPHQ: Patient Health Questionnaire.
gDASS: Depression Anxiety Stress Scale.
Clinically Significant Change
In terms of clinically significant change, we used Criterion B
(falling within 2 SD of the healthy mean), which is more
conservative than Criterion A (falling 2 SD below the
pathological mean) [46]. For GI symptoms, the mean GSRS
score for healthy controls is 12 (SD 11), leading to a cut-off
point of 34. In the immediate treatment group, 24 out of 36
participants (66%) met this criterion at posttreatment. For
HRQL, the mean IBS-QOL score for healthy controls is 5 (SD
11), leading to a cut-off point of 27. In the immediate treatment
group, 16 out of 36 participants (44%) met this criterion at
posttreatment. From another perspective, the qualitative range
for minimal to mild impairment on the IBS-QOL is 0-31. An
additional 2 participants would meet this slightly less stringent
criterion, leading to a total of 50% of participants in the
immediate treatment group showing an excellent response. This
yields a number needed to treat of 2.
After completing the 8-week follow-up questionnaires, the
waitlist group was crossed over to active treatment and was
given access to the app for 8 weeks. Paired-samples t tests
comparing their scores at the initial 8-week follow-up to their
scores posttreatment revealed significant improvement in HRQL,
catastrophizing, visceral anxiety, and fear of food, but not on
GI symptoms, depression, or anxiety (Table 4). Sensitivity
analysis using multiple imputation showed a similar pattern of
significance at the 5% level but with lower P values closer to
the significance level.
JMIR Mhealth Uhealth 2021 | vol. 9 | iss. 5 | e26152 | p. 9https://mhealth.jmir.org/2021/5/e26152
(page number not for citation purposes)
Hunt et alJMIR MHEALTH AND UHEALTH
XSL•FO
RenderX
Table 4. Improvement in the waitlist control group after crossover to active treatment.











aIBS-QOL: IBS Quality of Life.
bGSRS: Gastrointestinal Symptom Rating Scale.
cGI-COG: Gastrointestinal Cognitions Questionnaire.
dVSI: Visceral Sensitivity Index.
eFFQ: Fear of Food Questionnaire.
fPHQ: Patient Health Questionnaire.
gDASS: Depression Anxiety Stress Scale.
Three-month follow-up data were collected for all participants
(both the immediate treatment group and the waitlist group who
had been crossed over to treatment) between March and October
of 2020. Unfortunately, this meant that all follow-up data were
collected after the onset of the COVID-19 pandemic.
Nevertheless, participants (all of whom had had access to the
active treatment at this point) continued to show significant
improvement over baseline on all outcome variables except
depression (Table 5).
Table 5. Difference between baseline and 3-month follow-up data for all participants (N=121).











aIBS-QOL: IBS Quality of Life.
bGSRS: Gastrointestinal Symptom Rating Scale.
cGI-COG: Gastrointestinal Cognitions Questionnaire.
dVSI: Visceral Sensitivity Index.
eFFQ: Fear of Food Questionnaire.
fPHQ: Patient Health Questionnaire.
gDASS: Depression Anxiety Stress Scale.
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Finally, we assessed maintenance of treatment gains from
posttreatment to 3-month follow-up. Without exception, gains
were maintained, and there were no significant changes or
relapse in symptoms, except for a slight rise in depression. Thus,
even in the face of an incredibly stressful global pandemic, by
and large, our participants showed remarkable resilience, and
their HRQL, GI symptoms, GI-specific catastrophizing, anxiety,
and fear of food remained much improved (Table 6). This result
was confirmed in a sensitivity analysis using multiple imputation
(Table 7).
Table 6. Maintenance of gains from posttreatment to 3 months.











aIBS-QOL: Irritable Bowel Syndrome-Quality of Life.
bGSRS: Gastrointestinal Symptom Rating Scale.
cGI-COG: Gastrointestinal Cognitions Questionnaire.
dVSI: Visceral Sensitivity Index.
eFFQ: Fear of Food Questionnaire.
fPHQ: Patient Health Questionnaire.
gDASS: Depression Anxiety Stress Scale.
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Table 7. Intention-to-treat sensitivity analysis of within-group changes using multiple imputation.
Posttreatment to 3-month follow-up, all
participants (N=121)
8 weeks to posttreatment, waitlist
group (n=59)
0-8 weeks, immediate treatment
group (n=62)
Measure











aIBS-QOL: Irritable Bowel Syndrome-Quality of Life.
bGSRS: Gastrointestinal Symptom Rating Scale.
cGI-COG: Gastrointestinal Cognitions Questionnaire.
dVSI: Visceral Sensitivity Index.
eFFQ: Fear of Food Questionnaire.
fPHQ: Patient Health Questionnaire.
gDASS: Depression Anxiety Stress Scale.
Attrition
There was significant attrition from the study in both the
immediate treatment and waitlist control groups (see Figure 2
for the flow chart of study enrollment). An independent-samples
t test demonstrated that the only predictors of attrition at the
8-week follow-up were more severe visceral sensitivity
(t119=2.18, P=.03) and fear of food (t119=1.79, P=.08) for
participants in both the immediate treatment and waitlist group.
About half of the participants (21 out of 44) in the waitlist
control group who were offered crossover to active treatment
were lost to follow-up at their posttreatment assessment. None
of the measures at 8 weeks predicted attrition in this group. Of
the 58 participants across both groups who completed the active
treatment and the posttreatment questionnaires, 14 were lost to
follow-up prior to the 3-month assessment. Participants who
were lost to follow-up at that point were more likely to be less
stressed (t56=2.19, P=.03), catastrophized less (t56=2.21, P=.03),
and were somewhat less depressed (t56=1.72, P=.09) at
posttreatment.
Mediation
Another aim of the study was to test whether changes in
catastrophic thinking, visceral sensitivity, and fear of food would
at least partially mediate reductions in GI symptom severity
and improvement in quality of life.
The simple mediator models for GI symptom severity showed
that changes in visceral anxiety, catastrophizing, and fear of
food were all significant mediators of the relationship between
treatment and GI symptom severity. Participants assigned to
immediate treatment had a greater decrease in visceral anxiety,
catastrophizing, and fear of food, and participants who had a
greater decrease in visceral anxiety, catastrophizing, and fear
of food had lower GI symptom severity at 8 weeks while
controlling for baseline GI symptom severity (Table 8). The
statistically significant direct effect for each of the simple
models indicated that treatment directly influenced GI symptom
severity independent of the indirect effect of the mediating
variables. The parallel multiple mediator model indicated that
the indirect effects of visceral anxiety and fear of food were
independent mediators, but the effect of catastrophizing was
not significant (bias-corrected 95% CI included zero) and its
effect is taken up by the other mediators. Once again there was
a significant direct effect of treatment independent of mediators
on GI symptom severity (P<.001).
Participants assigned to immediate treatment had a greater
decrease in visceral anxiety, catastrophizing, and fear of food,
and participants who had a greater decrease in visceral anxiety,
catastrophizing, and fear of food had lower scores on IBS-QOL
at 8 weeks while controlling for baseline IBS-QOL (Table 8).
The statistically significant direct effect for the model including
fear of food indicated that treatment directly influenced quality
of life independent of the indirect effect of fear of food.
However, having accounted for the effect of change in visceral
anxiety and catastrophizing, no statistically significant direct
effect of treatment remained. The parallel multiple mediator
model indicated statistically significant indirect effects of the
three mediators with no direct effect of treatment (Table 8).
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Table 8. Direct and indirect mediation results.
IBSb quality of lifeGIa symptom severityMeasure
P valueEffect (95% BCI)P valueEffect (95% BCIc)
Visceral anxiety
<.001–12.2 (–18.62 to –6.4).002–4.3 (–7.0 to –1.8)Indirect
.08–4.6 (–9.8 to –.56).007–5.1 (–8.8 to –1.4)Direct
GI-specific catastrophizing
<.001–15.4 (–21.6 to –9.6).007–3.7 (–7.1 to –1.2)Indirect
.67–1.4 (–7.9 to 5.1).02–5.6 (–10.2 to –1.1)Direct
Fear of food
<.001–9.8 (–16.3 to –3.8).003–4.0 (–7.2 to –1.5)Indirect
.02–7.0 (–12.7 to –1.4).005–5.4 (–9.1 to –1.6)Direct
Parallel multiple mediator model
.83–.5 (–5.2 to 4.2)<.001–9.4 (–13.5 to –5.3)Direct
N/A–7.0 (–11.3 to –3.4)N/Ad–3.4 (–6.2 to –1.0)Visceral anxiety
N/A–5.1 (–9.0 to –1.8)N/A1.8 (–1.0 to 4.4)COGe
N/A–4.3 (–8.3 to –1.2)N/A–2.7 (–5.5 to –0.8)Fear of food
aGI: gastrointestinal.
bIBS: irritable bowel syndrome.




Univariate analysis of the data revealed that Rome IV criteria
moderated the effectiveness of the treatment. That is, there was
a significant interaction between condition and Rome IV status
such that the app was more helpful to the participants who
reported meeting stringent Rome IV criteria for IBS at baseline
than for those who did not, for both GI symptoms (F3,76=2.919,
P=.04<.0) and HRQL (F3,76=6.652, P=.001). The only
difference at baseline between those who met the criteria and
those who did not was severity of GI symptoms (t144=3.75,
P<.001). No other baseline variables were significantly different.
When the sample was restricted to only those individuals who
met strict Rome IV criteria, the advantage of the treatment group
over the waitlist group was even more marked for improvement
in GI symptoms (F1,56=30.2, P<.001), HRQL (F1,56=47.42,
P<.001), catastrophizing (F1,56=51.10, P<.001), visceral anxiety
(F1,56=28.84, P<.001), and fear of food (F1,56=22.11, P<.001).
We also examined whether IBS subtype moderated the efficacy
of the app; it did not.
Dose-Dependent Response
Because the app itself tracks objective progress through the
modules, we were able to examine the effect of “dose”
(measured as components of the app accessed) on outcome. The
majority of participants in the immediate treatment group who
completed follow-up surveys finished just shy over 3 modules
(mean 3.2, SD 2, median 2.9). Only one participant completed
all possible modules. Dosage was marginally correlated with
improvement in HRQL (r=0.33, P=.07) and depression (r=0.33,
P=.08), but was not directly correlated with improvement in GI
symptoms, changes in catastrophizing, or visceral anxiety. This
suggests that the more participants used the app, the more their
quality of life and depressive symptoms improved. These results
also suggest that the primary change components in the app
with respect to catastrophizing and visceral anxiety occurred
early in the modules.
Discussion
Principal Findings
The purpose of this study was two-fold. First, we tested the
efficacy of a cognitive behavioral intervention for IBS delivered
via a digital self-help app, with no therapist feedback or
involvement. Completer analyses yielded statistically and
clinically significant improvement, with treatment having a
positive impact on both GI symptom severity and quality of
life. Intention-to-treat sensitivity analysis using multiple
imputation replicated those findings. After treatment, individuals
reported significantly lower levels of IBS symptoms and less
impairment to their quality of life. Effect sizes for the primary
outcomes and most of the secondary outcomes were all in the
very large range. This 8-week intervention appears to have
substantially reduced the burden of illness compared to that of
waitlist controls.
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Second, we tested whether reductions in IBS-specific
catastrophic thinking, visceral sensitivity, and fear of food might
mediate the efficacy of treatment. Reductions in these three
variables did appear to mediate the impact of treatment on
HRQL, but not on GI symptoms themselves. The app worked
by reducing catastrophic thinking, visceral sensitivity to GI
symptoms, and fear of food, which in turn improved individuals’
quality of life. This is consistent with prior findings about the
impact of CBT on IBS. Additionally, changes in catastrophizing
and visceral anxiety were observed in participants who had only
completed the preliminary modules of the app. This is consistent
with the idea that psychoeducation and relaxation can promote
cognitive reframing and can reduce anxiety about visceral
sensations.
Overall, we are strongly encouraged by the results of this study,
which appear to suggest that effective CBT for IBS can be
successfully delivered via an app. The Zemedy app seems to
be an effective means to improve the lives of individuals with
IBS. Zemedy, which is already in the App Store and Google
Play Store for download, could dramatically increase the
accessibility of effective treatment for this debilitating disorder.
Limitations
This study had a number of limitations. The first was the lack
of a placebo control condition. Patients with IBS typically show
high placebo response rates [47], although the placebo effect is
reduced when individuals meet more stringent (ie, Rome IV)
diagnostic criteria. Future trials of the Zemedy app (including
an ongoing trial registered as NCT04665271 on
Clinicaltrials.gov) will include an active placebo control (sham
app) rather than relying on a simple waitlist.
The second major limitation was the lack of rigorous diagnostic
interviewing or explicit physician confirmation of the IBS
diagnosis. Our inclusion criteria were self-reported as a prior
physician diagnosis of IBS and/or meeting stringent Rome IV
criteria. Five participants had no physician diagnosis but met
Rome IV criteria. Thirty participants reported having been
diagnosed by a physician but did not meet stringent Rome IV
criteria. Of those, 7 would have met Rome III [1] criteria. The
remaining individuals failed to meet either the duration or
severity criteria.
The choice to include participants who did not meet Rome IV
criteria was made because the aim of the study was to determine
the efficacy of the app for individuals who believe they have
IBS and are searching for self-help materials. The app will be
accessible to all, and even those who perceive they have IBS
without a clinical diagnosis or meeting criteria will use it. Thus,
it is important to test the app among anyone who believes it to
be relevant to their life. Interestingly, individuals who did meet
criteria for IBS actually showed a significantly better response
to the app. Thus, including individuals who might not have met
strict Rome IV criteria is actually more conservative and more
ecologically valid. The app includes educational material about
the importance of a thorough differential diagnostic evaluation,
and especially the importance of ruling out other potential causes
of GI symptoms (such as celiac disease and inflammatory bowel
diseases). Moving forward, it may be important for the app to
encourage people who do not meet Rome IV criteria to consult
with their physicians about other possible causes of their
symptoms.
The third limitation was the rate of attrition, with 36% not
completing follow-up measures. Of those who completed
8-week follow-up measures, most had not made it through a
substantial portion of the app’s content. Nevertheless, the
attrition rate from treatment of 36% is actually lower than the
rate of 47% on average typically found in studies of online
behavioral health interventions [48].
In addition, people did not drop out entirely at random.
Participants who dropped out during the initial treatment phase
had significantly higher rates of visceral anxiety and fear of
food at baseline (although there were no other significant
differences). Since CBT for IBS typically encourages acceptance
of visceral sensations and reduction of behavioral avoidance
(especially avoidance of food and food-related social situations),
the treatment may have seemed particularly challenging for
those individuals. This might represent a population requiring
more personal guidance, encouragement, and support from
in-person therapy.
A fourth limitation of the study was the inability to statistically
establish the temporal precedence of the proposed mediators of
change. In the study design, there was no midpoint survey to
show that visceral anxiety, catastrophizing, and fear of food
changed before quality of life improved. We did not include
this intermediate survey during the treatment phase because we
were concerned that it would increase attrition of participants,
although a future study of the app would benefit from data
obtained at this point.
A fifth limitation is that the PHQ-9 is a poor measure of
depression severity because it only measures symptom frequency
and does not take intensity of symptoms into account. For
example, at baseline, someone might indicate feeling tired or
having little energy nearly every day (scoring a 3), because they
are so anergic they can barely get out of bed. By the end of a
trial, they might still indicate feeling tired or having little energy
nearly every day (scoring a 3) because they still feel chronically
fatigued, but they are getting up and going to work every day.
The severity of their anergia would have declined significantly,
but the PHQ-9 would reflect no change. Furthermore, the item
that assesses suicidality makes no distinctions at all with respect
to passive versus active ideation, nor does it capture intent. An
individual who has passive suicidal ideation daily, but no intent,
would actually score higher than an individual who experiences
less frequent, but intense active suicidal ideation with wavering
intent. Although the PHQ-9 has been used in many other clinical
trials of behavioral health interventions, and it did show
significant improvement over the course of this trial in the
completer sample (but not in the intention-to-treat analyses),
we were dissatisfied with its sensitivity to treatment effects.
Future studies of the app will employ more sensitive measures.
A sixth limitation is that we did not assess concurrent medication
use. However, there is no reason to believe that medication use
would have been different across the immediate treatment and
control groups.
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Finally, the last phase of the trial occurred during the COVID-19
global pandemic. Since all waitlist participants had already been
crossed over to the active treatment phase, the 3-month
follow-up data may be less reflective of the enduring effects of
the treatment and more reflective of the massive social,
economic, and personal upheaval the pandemic has caused.
Indeed, the end of the treatment phase for all participants
coincided with the COVID-19 pandemic’s arrival in the United
States. With massive shutdowns and quarantines, it is highly
likely that distress increased for all participants. The fact that
treatment gains were generally maintained and that participants
remained much improved over baseline (except for some
recurrence of depression), even in the face of an unprecedented
global health crisis, is encouraging.
Conclusion
Despite the limitations, we believe that this study is of
significant value. It successfully demonstrated the efficacy of
an app that provided CBT for IBS patients. The intervention
was not restricted by geography or scheduling constraints, and
required no face-to-face contact with a clinician, aspects that
dramatically increase the accessibility and portability of
treatment. Despite its relatively benign physical profile, IBS
can be an extraordinarily debilitating condition. Finding novel
ways to disseminate evidence-based, effective treatments
remains an important challenge, and Zemedy is a promising
and effective way to help those suffering from IBS.
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